189 related articles for article (PubMed ID: 34333871)
1. Drug use evaluation: A two-year retrospective review of the effectiveness and tolerability of agomelatine versus mirtazapine in patients with depressive disorder.
Leung SM
Brain Behav; 2021 Aug; 11(8):e2311. PubMed ID: 34333871
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response.
Papakostas GI; Nielsen RZ; Dragheim M; Tonnoir B
J Psychiatr Res; 2018 Jun; 101():72-79. PubMed ID: 29554497
[TBL] [Abstract][Full Text] [Related]
3. Other Antidepressants.
Schwasinger-Schmidt TE; Macaluso M
Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
[TBL] [Abstract][Full Text] [Related]
4. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
[TBL] [Abstract][Full Text] [Related]
5. Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control.
Kasper S; Corruble E; Hale A; Lemoine P; Montgomery SA; Quera-Salva MA
Int Clin Psychopharmacol; 2013 Jan; 28(1):12-9. PubMed ID: 23023074
[TBL] [Abstract][Full Text] [Related]
6. Agomelatine versus other antidepressive agents for major depression.
Guaiana G; Gupta S; Chiodo D; Davies SJ; Haederle K; Koesters M
Cochrane Database Syst Rev; 2013 Dec; (12):CD008851. PubMed ID: 24343836
[TBL] [Abstract][Full Text] [Related]
7. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials.
Huang KL; Lu WC; Wang YY; Hu GC; Lu CH; Lee WY; Hsu CC
Aust N Z J Psychiatry; 2014 Jul; 48(7):663-71. PubMed ID: 24604920
[TBL] [Abstract][Full Text] [Related]
8. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT.
Kessler D; Burns A; Tallon D; Lewis G; MacNeill S; Round J; Hollingworth W; Chew-Graham C; Anderson I; Campbell J; Dickens C; Macleod U; Gilbody S; Davies S; Peters TJ; Wiles N
Health Technol Assess; 2018 Nov; 22(63):1-136. PubMed ID: 30468145
[TBL] [Abstract][Full Text] [Related]
9. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
Clayton AH; Baker RA; Sheehan JJ; Cain ZJ; Forbes RA; Marler SV; Marcus R; Berman RM; Thase ME
BMC Res Notes; 2014 Jul; 7():459. PubMed ID: 25037144
[TBL] [Abstract][Full Text] [Related]
10. How to switch to agomelatine after an unsuccessful try with paroxetine or venlafaxine.
Lejoyeux M; Matharan S; de Bodinat C
CNS Spectr; 2015 Feb; 20(1):29-38. PubMed ID: 24330826
[TBL] [Abstract][Full Text] [Related]
11. Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.
Khoo AL; Zhou HJ; Teng M; Lin L; Zhao YJ; Soh LB; Mok YM; Lim BP; Gwee KP
CNS Drugs; 2015 Aug; 29(8):695-712. PubMed ID: 26293743
[TBL] [Abstract][Full Text] [Related]
12. A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.
Papakostas GI; Homberger CH; Fava M
J Psychopharmacol; 2008 Nov; 22(8):843-8. PubMed ID: 18308801
[TBL] [Abstract][Full Text] [Related]
13. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression.
Murphy GM; Hollander SB; Rodrigues HE; Kremer C; Schatzberg AF
Arch Gen Psychiatry; 2004 Nov; 61(11):1163-9. PubMed ID: 15520364
[TBL] [Abstract][Full Text] [Related]
14. [Agomelatine in the treatment of major depressive disorder: assessment of the efficacy and tolerability].
Filippova NV; Barylnik YB; Shuldyakov AA; Antonova AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(5):154-161. PubMed ID: 31317905
[TBL] [Abstract][Full Text] [Related]
15. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis.
Watanabe N; Omori IM; Nakagawa A; Cipriani A; Barbui C; McGuire H; Churchill R; Furukawa TA;
CNS Drugs; 2010 Jan; 24(1):35-53. PubMed ID: 20030418
[TBL] [Abstract][Full Text] [Related]
16. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.
Hale A; Corral RM; Mencacci C; Ruiz JS; Severo CA; Gentil V
Int Clin Psychopharmacol; 2010 Nov; 25(6):305-14. PubMed ID: 20856123
[TBL] [Abstract][Full Text] [Related]
17. Effects of agomelatine and mirtazapine on sleep disturbances in major depressive disorder: evidence from polysomnographic and resting-state functional connectivity analyses.
Mi WF; Tabarak S; Wang L; Zhang SZ; Lin X; Du LT; Liu Z; Bao YP; Gao XJ; Zhang WH; Wang XQ; Fan TT; Li LZ; Hao XN; Fu Y; Shi Y; Guo LH; Sun HQ; Liu L; Si TM; Zhang HY; Lu L; Li SX
Sleep; 2020 Nov; 43(11):. PubMed ID: 32406918
[TBL] [Abstract][Full Text] [Related]
18. Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR).
Kessler DS; MacNeill SJ; Tallon D; Lewis G; Peters TJ; Hollingworth W; Round J; Burns A; Chew-Graham CA; Anderson IM; Shepherd T; Campbell J; Dickens CM; Carter M; Jenkinson C; Macleod U; Gibson H; Davies S; Wiles NJ
BMJ; 2018 Oct; 363():k4218. PubMed ID: 30381374
[TBL] [Abstract][Full Text] [Related]
19. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.
Goodwin GM; Emsley R; Rembry S; Rouillon F;
J Clin Psychiatry; 2009 Aug; 70(8):1128-37. PubMed ID: 19689920
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Agomelatine vs Paroxetine Hydrochloride in Chinese Han Patients with Major Depressive Disorder: A Multicentre, Double-Blind, Noninferiority, Randomized Controlled Trial.
Yu YM; Gao KR; Yu H; Shen YF; Li HF
J Clin Psychopharmacol; 2018 Jun; 38(3):226-233. PubMed ID: 29620692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
